https://orcid.org/0000-0002-6793-3273
References
- Orbach D , BrennanB, PaoliAet al. Conservative strategy in infantile fibrosarcoma is possible: The European Paediatric Soft Tissue Sarcoma Study Group experience. Eur. J. Cancer57, 1–9 (2016).
- Sparber-Sauer M , VokuhlC, SeitzGet al. The impact of local control in the treatment of children with advanced infantile and adult-type fibrosarcoma: experience of the cooperative weichteilsarkom studiengruppe (CWS). J. Pediatr. Surg.55(9), 1740–1747 (2020).
- Orbach D , Sparber-SauerM, LaetschTet al. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: international consensus and remaining controversies. Eur. J. Cancer137, 183–192 (2020).
- Loh M , AhnP, Perez-AtaydeA, GebhardtM, ShambergerR, GrierH. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children’s Hospital, Boston. J. Pediatr. Hematol. Oncol.24, 722–726 (2002).
- Weiss A , GillJ, GoldbergJet al. Advances in therapy for pediatric sarcomas. Curr. Oncol. Rep.16, 395 (2014).
- Orbach D , ReyA, CecchettoGet al. Infantile fibrosarcoma: management based on the European experience. J. Clin. Oncol.28, 318–323 (2010).
- Laetsch T , DuboisS, MascarenhasLet al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: Phase I results from a multicentre, open-label, Phase I/II study. Lancet Oncol.19, 705–714 (2018).
- Drilon A , LaetschT, KummarSet al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N. Engl. J. Med.378, 731–739 (2018).
- Hong DS , DuboisSG, KummarSet al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three Phase I/II clinical trials. Lancet Oncol.21(4), 531–540 (2020).
- Lengliné E , PeronJ, VanierAet al. Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment. Lancet Oncol.22, e430–e434 (2021).
- Koscielniak E , BlankB, VokuhlCet al. Long-term clinical outcome and prognostic factors of children and adolescents with localized rhabdomyosarcoma treated on the CWS-2002P protocol. Cancers (Basel)14(4), 899 (2022).
- Rodary C , FlamantF, DonaldsonSS. An attempt to use a common staging system in rhabdomyosarcoma: a report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP). Med. Pediatr. Oncol.17(3), 210–215 (1989).
- Rosner B . In: Fundamentals of Biostatistics:Chapter8. Hypothesis testing: Two-sample inference (6th Edition).RosnerB ( Ed.). Thomson-Brooks/Cole, CA, USA, 1–868 (2006).
- Cucherat M , LaporteS, DelaitreOet al. From single-arm studies to externally controlled studies. Methodological considerations and guidelines. Therapies75, 21–27 (2020).
- Austin P , StuartE. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med.34, 3661–3679 (2015).
- Doz F , van TilburgCM, GeoergerBet al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro. Oncol.24(6), 997–1007 (2022).
- Waguespack SG , DrilonA, LinJJet al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur. J. Endocrinol.186(6), 631–643 (2022).
- Drilon A , TanDSW, LassenUNet al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers. JCO Precis. Oncol.6, e2100418 (2022).
- Seeger J , DavisK, IannaconeMet al. Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials. Pharmacoepidemiol Drug Saf.29, 1382–1392 (2020).
- Austin P . The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat. Med.33, 1242–1258 (2014).
- van Tilburg CM , PfaffE, PajtlerKWet al. The Pediatric Precision Oncology INFORM Registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov.11(11), 2764–2779 (2021).